P  - Caution when used during pregnancy

L  - Caution when used during lactation

Molecule Info

 
Indication & Dosage Oral
Hypertension
Adult: Initially, 2 mg once daily preferably in the morning; increase to 4 mg daily after 3-4 wk if necessary. May be increased further to 6 mg in some patients.
Hepatic impairment: Severe impairment: Reduce dose.

Special Populations: Liver disease: Initially 2 mg once daily; may be increased to 4 mg depending on response.
Administration May be taken with or without food.
Contraindications Within 1 mth of MI, cardiogenic shock, unstable angina, aortic stenosis.
Special Precautions Conduction abnormalities, congenital or acquired QT prolongation, poor cardiac reserve. Hepatic impairment. Pregnancy and lactation.
Adverse Drug Reactions Headache, flushing, oedema, dizziness, palpitations, aggravation of angina, increased alkaline phosphatase. Rarely asthenia, rash (e.g. erythema and itching), gastric upset, nausea, gum hyperplasia, polyuria, muscle cramps, mood disturbances.
Drug Interactions Additive hypotensive effect with other antihypertensives (e.g. diuretics, β-blockers, ACE inhibitors). Increased plasma concentration with cimetidine. Elimination and metabolism may be altered by potent CYP3A4 inhibitors and inducers.
Potentially Fatal: Increased risk of ventricular arrhythmias with drugs that prolong QT interval (e.g. class I and III antiarrhythmics, TCAs, certain antipsychotics, antibiotics and antihistamines).  Please consult detailed drug interactions before prescribing.
Food Interaction Plasma concentrations increased with grapefruit juice.
Storage Oral: Store below 30°C (86°F).
Pharmacology Lacidipine is a potent dihydropyridine calcium antagonist mainly selective for calcium channels in the vascular smooth muscle. It dilates peripheral arterioles resulting in reduced peripheral vascular resistance and blood pressure.
Absorption: Rapidly but poorly absorbed from the GIT (oral).
Distribution: Protein-binding: >95%
Metabolism: Extensive first-pass metabolism.
Excretion: In the bile via faeces (70%, as metabolites), via urine (remaining dose); 13-19 hr (elimination half-life).
ATC Classification C08CA09 - lacidipine; Belongs to the class of selective dihydropyridine derivative calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

Brand/Product Info


Total Products : 7       
Brand Name Manufacturer/Marketer Composition Dosage Form Pack Size & Price
L-CARDIN-2 Drug International Ltd Lacidipine hydrochloride BP 2mg Tablet (film-coated) 2mg x 50's: 150.00 MRP
LACICARD-2 Aristopharma Ltd. Lacidipine hydrochloride BP 2mg Tablet (film-coated) 2mg x 50's: 200.00 MRP
LACICARD-4 Aristopharma Ltd. Lacidipine hydrochloride BP 4mg Tablet (film-coated) 4mg x 30's: 180.00 MRP
Lacidip 2 Incepta Pharmaceuticals Limited Lacidipine BP 2 mg Film Coated Tablet 10x5's:MRP 200 Tk
Lacidip 4 Incepta Pharmaceuticals Limited Lacidipine BP 4 mg Film Coated Tablet 10x3's:MRP 180 Tk
LACITAB-2 The Acme Laboratories Ltd. Lacidipine hydrochloride BP 2mg Tablet (film-coated) 2mg x 50's: 200.50 MRP
LACITAB-4 The Acme Laboratories Ltd. Lacidipine hydrochloride BP 4mg Tablet (film-coated) 4mg x 30's: 180.60 MRP